Recruiting for ALT-GIST

The ALT-GIST clinical trial, a randomised phase II trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumour (GIST), has only eight patients left to randomise. This trial is the only means of accessing subsidised regorafenib in Australia at present. Due … Read More

September 19, 2017

Preceptorship in Rectal Cancer

An educational model for understanding contemporary oncology management through advances in clinical trials “The Preceptorship” is an interactive learning model developed by Professor Eva Segelov covering landmark clinical trials in specific cancers, with mentorship from experts in the field. It has been applied in the areas of lung, colorectal, upper gastro-intestinal and … Read More

September 18, 2017

NABNEC@ESMO

Dr Mustafa Khasraw, Principal Investigator, NABNEC recently presented a NABNEC poster at ESMO.  The aim of the NABNEC trial is to determine the safety and efficacy of carboplatin plus nab-paclitaxel in comparison with carboplatin plus etoposide for the treatment of grade 3, advanced gastrointestinal neuroendocrine carcinomas. In addition, the trial … Read More

September 18, 2017

AGITG Trial News

The AGITG currently has eight  studies open to recruitment and ten  studies in follow up. The  table below details  the trials that  are currently  accruing patients. Recruited Target ACTICCA-1- Gallbladder carcinoma 2 50 ALT-GIST- GI Stromal Tumour 19 60 ASCOLT — Colorectal cancer 227 300 CONTROL NETs — NeuroEndocrine Tumour … Read More

September 4, 2017

AGITG Best Site Award

  All clinical trial sites actively involved in AGITG Studies are invited to submit a brief application of 500 words or less explaining why your site should receive this prestigious award. Sites will be judged on a number of criteria including but not restricted to: Level of Enthusiasm across the whole … Read More

August 10, 2017

New CommNETS Executive Committee Announced

The Commonwealth Neuroendocrine Tumour Group (CommNETS) formed in 2015 and brings together NETS researchers, clinicians and consumers from Australia, New Zealand and Canada under one umbrella to encourage the development of clinical trials in neuroendocrine cancers. Mission: To improve the outcomes of NET patients through accelerated collaboration between patients, clinicians … Read More

August 10, 2017

Report shows clinical trials pay off for safety & quality

A new report evaluating the economic impact of clinical trials conducted by research networks, was published this week by the Australian Clinical Trials Alliance (ACTA) and the Australian Commission on Safety and Quality in Healthcare (ACSQHC). This report evolved after growing international evidence suggested that programs of high-quality investigator-initiated clinical … Read More

August 4, 2017

New NEC Clinical Trial Open for Recruitment

We are pleased to be able to promote our latest National Neuroendocrine Carcinoma (NEC) clinical trial – ‘NABNEC’, lead by the AGITG’s Principal Investigator,  Dr Mustafa Khasraw. This clinical trial aims to establish the best treatment for this very rare disease by comparing two chemotherapy regiments – nab-paclitaxel with carboplatin … Read More

August 3, 2017

Dr Lorraine Chantrill gets Gutsy for GI Cancer

Support Dr Lorraine Chantrill with her Larapinta Gutsy Challenge Trek. Dr. Lorraine Chantrill, AGITG Board Member and medical oncologist with a focus on pancreatic cancer research, will be heading off on her 80km trek of the Larapinta Trail on Sunday 6th August. Her motivation for setting herself this challenge is personal. As … Read More

July 27, 2017

Key ASCO Presentations on GI Cancer

A number of AGITG members attended this year’s American Society of Clinical Oncology (ASCO) meeting in Chicago (2-6 June). Following ASCO NEJM Journal Watch Oncology and Hematology have published an article which provides reviews by Associate Editor David H. Ilson, MD, PhD, of key presentations on new Gastro-Intestinal cancer treatments. … Read More

June 21, 2017